.Attribute Medicine, Released online: 09 October 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec acquired FDA confirmation after a damaging test, which highlights the numerous difficulties as well as difficulties of medication development in this particular setting.